Table 1.
Strains and plasmids used in this study
| Strain or plasmid | Relevant characteristicsa | Source or reference |
|---|---|---|
| Strains | ||
| E22 | REPEC serotype O103:H2, Rifr | 14 |
| E22 ΔregR | E22 ΔregR, Rifr | This study |
| E22 Δ2 | E22 ΔregR ΔEcE22_5293, Kanr Rifr | This study |
| E22 ΔsefA::kan | E22 ΔsefA, Kanr Rifr | This study |
| MC4100 | F− araD139 Δ(argF-lac)U169 rpsL150 relA1 flbB5301 deoC1 ptsF25 rbsR thiA | 66 |
| BL21(DE3) | F− ompT hsdSB(rB− mB−) gal dcm (DE3) | New England BioLabs |
| TOP10 | F− mcrA Δ(mrr− hsdRMS− mcrBC) ϕ80lacZΔM15 ΔlacX74 nupG recA1 araD139 Δ(ara-leu)7697 galE15 galK16 rpsL(Strr) endA1 λ− | Invitrogen |
| Plasmids | ||
| pGEM-T Easy | High-copy-no. vector, Apr | Promega |
| pCR2.1-TOPO | High-copy-no. vector, Apr Kanr | Invitrogen |
| pACYC184 | Medium-copy-no. vector, Cmr Tcr | 67 |
| pFT-A | Low-copy-no. vector, flp Apr | 68 |
| pKD4 | FRT-flanked kan gene, Kanr Apr | 36 |
| pKD46 | Low-copy-no. vector, PBAD-λred Apr | 36 |
| pMU2385 | Single-copy-no. transcriptional fusion vector, Tpr | 69 |
| pMAL-c2x | Expression vector for N-terminal MBP fusion proteins | New England Biolabs |
| pYS1 | pGEM-T Easy+ΔregR::kan | This study |
| pYS2 | pCR2.1-TOPO+regR | This study |
| pYS3 | pACYC184+regR | This study |
| pYS4 | pGEM-T Easy+sefA1 | This study |
| pYS5 | pGEM-T Easy+sefA2 | This study |
| pYS7 | pGEM-T Easy+sefA3 | This study |
| pYS8 | pGEM-T Easy+sefA4 | This study |
| pYS9 | pMU2385+sefA1 | This study |
| pYS10 | pMU2385+sefA2 | This study |
| pYS11 | pMU2385+sefA3 | This study |
| pYS12 | pMU2385+sefA4 | This study |
| pYS13 | pGEM-T Easy+regR | This study |
| pYS14 | pMAL-c2x+regR | This study |
| pYS15 | pGEM-T Easy+sefAprom | This study |
| pYS16 | pGEM-T Easy+sefAcontrol | This study |
| pYS17 | pGEM-T Easy+ΔsefA::kan | This study |
| pYS21 | pGEM-T Easy+ ΔEcE22_5293::kan | This study |
a
Apr, ampicillin resistance; Cmr, chloramphenicol resistance; Kanr, kanamycin resistance; Tcr, tetracycline resistance; Tpr, trimethoprim resistance.